Works by Woerle, Hans-Juergen

Results: 41

Letter to the editor regarding: 'Pharmacokinetics of teneligliptin in subjects with renal impairment.' Halabi et al., Clinical Pharmacology in Drug Development 2013;2:246-254.

Published in:

Clinical Pharmacology in Drug Development, 2014, v. 3, n. 5, p. 417, doi. 10.1002/cpdd.119

By:

Graefe‐Mody, Ulrike;
Friedrich, Christian;
von Eynatten, Maximilian;
Thiemann, Sandra;
Heise, Tim;
Woerle, Hans‐Juergen

Publication type:

Article

Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: A multinational, 24-week, randomized, clinical trial.

Published in:

Journal of Diabetes Investigation, 2015, v. 6, n. 6, p. 692, doi. 10.1111/jdi.12346

By:

Chen, Yuhong;
Ning, Guang;
Wang, Changjiang;
Gong, Yan;
Patel, Sanjay;
Zhang, Candice;
Izumoto, Toshiyasu;
Woerle, Hans‐Juergen;
Wang, Weiqing

Publication type:

Article

Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?

Published in:

2017

By:

Marx, Nikolaus;
McGuire, Darren K.;
Perkovic, Vlado;
Woerle, Hans-Juergen;
Broed, Uli C.;
von Eynatten, Maximilian;
George, Jyothis T.;
Rosenstock, Julio;
Broedl, Uli C

Publication type:

journal article

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.

Published in:

Journal of Clinical Investigation, 2014, v. 124, n. 2, p. 499, doi. 10.1172/JCI72227

By:

Ferrannini, Ele;
Muscelli, Elza;
Frascerra, Silvia;
Baldi, Simona;
Mari, Andrea;
Heise, Tim;
Broedl, Uli C.;
Woerle, Hans-Juergen

Publication type:

Article

Effect of Multiple Oral Doses of Linagliptin on the Steady-State Pharmacokinetics of a Combination Oral Contraceptive in Healthy Female Adults.

Published in:

Clinical Drug Investigation, 2011, v. 31, n. 9, p. 643, doi. 10.2165/11590240-000000000-00000

By:

Friedrich, Christian;
Port, Andreas;
Ring, Arne;
Graefe-Mody, Ulrike;
Giessmann, Thomas;
Iovino, Mario;
Woerle, Hans-Juergen

Publication type:

Article

Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial.

Published in:

Diabetes Care, 2015, v. 38, n. 2, p. e15, doi. 10.2337/dc14-1684

By:

Laakso, Markku;
Rosenstock, Julio;
Groop, Per-Henrik;
Barnett, Anthony H.;
Gallwitz, Baptist;
Hehnke, Uwe;
Tamminen, Ilkka;
Patel, Sanjay;
von Eynatten, Maximilian;
Woerle, Hans-Juergen

Publication type:

Article

Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial.

Published in:

Diabetes Care, 2014, v. 37, n. 5, p. 1480, doi. 10.2337/dc13-2338

By:

Perkins, Bruce A.;
Cherney, David Z. I.;
Partridge, Helen;
Soleymanlou, Nima;
Tschirhart, Holly;
Zinman, Bernard;
Fagan, Nora M.;
Kaspers, Stefan;
Woerle, Hans-Juergen;
Broedl, Uli C.;
Johansen, Odd-Erik

Publication type:

Article

C-Peptide Levels in Latent Autoimmune Diabetes in Adults Treated With Linagliptin Versus Glimepiride: Exploratory Results From a 2-Year Double-Blind, Randomized, Controlled Study.

Published in:

Diabetes Care, 2014, v. 37, n. 1, p. e11, doi. 10.2337/dc13-1523

By:

Johansen, Odd Erik;
Boehm, Bernhard O.;
Grill, Valdemar;
Torjesen, Peter A.;
Bhattacharya, Sudipta;
Patel, Sanjay;
Wetzel, Kristiane;
Woerle, Hans-Juergen

Publication type:

Article

Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study.

Published in:

2013

By:

Yki-Järvinen, Hannele;
Rosenstock, Julio;
Durán-Garcia, Santiago;
Pinnetti, Sabine;
Bhattacharya, Sudipta;
Thiemann, Sandra;
Patel, Sanjay;
Woerle, Hans-Juergen

Publication type:

journal article

Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes.

Published in:

Diabetes Care, 2013, v. 36, n. 12, p. 3875, doi. 10.2337/dc12-2718

By:

YKI-JÄRVINEN, HANNELE;
ROSENSTOCK, JULIO;
DURÁN-GARCIA, SANTIAGO;
PINNETTI, SABINE;
BHATTACHARYA, SUDIPTA;
THIEMANN, SANDRA;
PATEL, SANJAY;
WOERLE, HANS-JUERGEN

Publication type:

Article

Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction.

Published in:

2013

By:

Groop, Per-Henrik;
Cooper, Mark E;
Perkovic, Vlado;
Emser, Angela;
Woerle, Hans-Juergen;
von Eynatten, Maximilian

Publication type:

journal article

Linagliptin Lowers Albuminuria on Topof Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction.

Published in:

Diabetes Care, 2013, v. 36, n. 11, p. 3460, doi. 10.2337/dc13-0323

By:

GROOP, PER-HENRIK;
COOPER, MARK E.;
PERKOVIC, VLADO;
EMSER, ANGELA;
WOERLE, HANS-JUERGEN;
VON EYNATTEN, MAXIMILIAN

Publication type:

Article

Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study.

Published in:

2013

By:

McGill JB;
Sloan L;
Newman J;
Patel S;
Sauce C;
von Eynatten M;
Woerle HJ;
McGill, Janet B;
Sloan, Lance;
Newman, Jennifer;
Patel, Sanjay;
Sauce, Christophe;
von Eynatten, Maximilian;
Woerle, Hans-Juergen

Publication type:

journal article

Long-Term Efficacy and Safety of Linagliptinin Patients With Type 2 Diabetes and Severe Renal Impairment.

Published in:

Diabetes Care, 2013, v. 36, n. 2, p. 237, doi. 10.2337/dc12-0706

By:

MCGILL, JANET B.;
SLOAN, LANCE;
NEWMAN, JENNIFER;
PATEL, SANJAY;
SAUCE, CHRISTOPHE;
VON EYNATTEN, MAXIMILIAN;
WOERLE, HANS-JUERGEN

Publication type:

Article

Pharmacokinetics of single and multiple oral doses of 5 mg linagliptin in healthy Chinese volunteers.

Published in:

International Journal of Clinical Pharmacology & Therapeutics, 2012, v. 50, n. 12, p. 889, doi. 10.5414/CP201802

By:

Friedrich, Christian;
Xiaojin Shi;
Zeng, Peter;
Ring, Arne;
Woerle, Hans-Juergen;
Patel, Sanjay

Publication type:

Article

Incorrect description of mode of excretion of linagliptin.

Published in:

Drug, Healthcare & Patient Safety, 2010, v. 2, p. 93

By:

Woerle, Hans-Juergen;
Patel, Sanjay

Publication type:

Article

Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA–T2D<sup>™</sup> trial.

Published in:

Diabetes & Vascular Disease Research, 2015, v. 12, n. 6, p. 455, doi. 10.1177/1479164115579002

By:

Groop, Per-Henrik;
Cooper, Mark E.;
Perkovic, Vlado;
Sharma, Kumar;
Schernthaner, Guntram;
Haneda, Masakazu;
Hocher, Berthold;
Gordat, Maud;
Cescutti, Jessica;
Woerle, Hans-Juergen;
von Eynatten, Maximilian

Publication type:

Article

Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.

Published in:

Diabetes & Vascular Disease Research, 2015, v. 12, n. 4, p. 249, doi. 10.1177/1479164115579001

By:

McGill, Janet B.;
Yki-Järvinen, Hannele;
Crowe, Susanne;
Woerle, Hans-Juergen;
von Eynatten, Maximilian

Publication type:

Article

Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®).

Published in:

Diabetes & Vascular Disease Research, 2015, v. 12, n. 3, p. 164, doi. 10.1177/1479164115570301

By:

Marx, Nikolaus;
Rosenstock, Julio;
Kahn, Steven E;
Zinman, Bernard;
Kastelein, John J;
Lachin, John M;
Espeland, Mark A;
Bluhmki, Erich;
Mattheus, Michaela;
Ryckaert, Bart;
Patel, Sanjay;
Johansen, Odd Erik;
Woerle, Hans-Juergen

Publication type:

Article

Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment.

Published in:

Diabetes & Vascular Disease Research, 2014, v. 11, n. 1, p. 34, doi. 10.1177/1479164113507068

By:

McGill, Janet B;
Barnett, Anthony H;
Lewin, Andrew J;
Patel, Sanjay;
Neubacher, Dietmar;
von Eynatten, Maximilian;
Woerle, Hans-Juergen

Publication type:

Article

Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus.

Published in:

Diabetes Therapy, 2012, v. 3, n. 1, p. 1, doi. 10.1007/s13300-012-0010-y

By:

Rauch, Thomas;
Graefe-Mody, Ulrike;
Deacon, Carolyn;
Ring, Arne;
Holst, Jens;
Woerle, Hans-Juergen;
Dugi, Klaus;
Heise, Tim

Publication type:

Article

Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying.

Published in:

2011

By:

Nicolaus, Mathias;
Brödl, Julia;
Linke, Rainer;
Woerle, Hans-Juergen;
Göke, Burkhard;
Schirra, Jörg

Publication type:

journal article

Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes.

Published in:

Diabetologia, 2016, v. 59, n. 4, p. 700, doi. 10.1007/s00125-015-3845-8

By:

Muscelli, Elza;
Astiarraga, Brenno;
Barsotti, Elisabetta;
Mari, Andrea;
Schliess, Freimut;
Nosek, Leszek;
Heise, Tim;
Broedl, Uli;
Woerle, Hans-Juergen;
Ferrannini, Ele

Publication type:

Article

Linagliptin improves glycemic control after 1 year as add-on therapy to basal insulin in Asian patients with type 2 diabetes mellitus.

Published in:

Current Medical Research & Opinion, 2015, v. 31, n. 3, p. 503, doi. 10.1185/03007995.2015.1010638

By:

Sheu, Wayne H.-H.;
Park, Sung Woo;
Gong, Yan;
Pinnetti, Sabine;
Bhattacharya, Sudipta;
Patel, Sanjay;
Seck, Thomas;
Woerle, Hans-Juergen

Publication type:

Article

Efficacy and safety of linagliptin as monotherapy or add-on treatment in Asian patients with suboptimal glycemic control: a pooled analysis.

Published in:

Current Medical Research & Opinion, 2015, v. 31, n. 1, p. 99, doi. 10.1185/03007995.2014.964856

By:

Zhengpei Zeng;
Dong Seop Choi;
Mohan, Viswanathan;
Emser, Angela;
Siddiqui, Kamran;
Gong, Yan;
Patel, Sanjay;
Woerle, Hans-Juergen

Publication type:

Article

Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial.

Published in:

2013

By:

Zeng, Zhengpei;
Yang, Jin-Kui;
Tong, Nanwei;
Yan, Shengli;
Zhang, Xiling;
Gong, Yan;
Woerle, Hans-Juergen

Publication type:

Journal Article

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.

Published in:

2019

By:

Rosenstock, Julio;
Perkovic, Vlado;
Johansen, Odd Erik;
Cooper, Mark E.;
Kahn, Steven E.;
Marx, Nikolaus;
Alexander, John H.;
Pencina, Michael;
Toto, Robert D.;
Wanner, Christoph;
Zinman, Bernard;
Woerle, Hans Juergen;
Baanstra, David;
Pfarr, Egon;
Schnaidt, Sven;
Meinicke, Thomas;
George, Jyothis T.;
von Eynatten, Maximilian;
McGuire, Darren K.;
CARMELINA Investigators

Publication type:

journal article

The Role of Endogenous Incretin Secretion as Amplifier of Glucose-Stimulated Insulin Secretion in Healthy Subjects and Patients With Type 2 Diabetes.

Published in:

Diabetes, 2012, v. 61, n. 9, p. 2349, doi. 10.2337/db11-1701

By:

Woerle, Hans Juergen;
Carneiro, Lucianno;
Derani, Ayman;
Göke, Burkhard;
Schirra, Jörg

Publication type:

Article

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA<sup>®</sup>): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk

Published in:

Cardiovascular Diabetology, 2018, v. 17, p. 1, doi. 10.1186/s12933-018-0682-3

By:

Rosenstock, Julio;
Perkovic, Vlado;
Alexander, John H.;
Cooper, Mark E.;
Marx, Nikolaus;
Pencina, Michael J.;
Toto, Robert D.;
Wanner, Christoph;
Zinman, Bernard;
Baanstra, David;
Pfarr, Egon;
Mattheus, Michaela;
Broedl, Uli C.;
Woerle, Hans-Juergen;
George, Jyothis T.;
von Eynatten, Maximilian;
McGuire, Darren K.;
CARMELINA® investigators

Publication type:

Article

Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events.

Published in:

Cardiovascular Diabetology, 2015, v. 14, n. 1, p. 1, doi. 10.1186/s12933-015-0215-2

By:

Rosenstock, Julio;
Marx, Nikolaus;
Neubacher, Dietmar;
Seck, Thomas;
Patel, Sanjay;
Woerle, Hans-Juergen;
Johansen, Odd Erik

Publication type:

Article

Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin.

Published in:

Diabetologia, 2014, v. 57, n. 9, p. 1869, doi. 10.1007/s00125-014-3276-y

By:

Zimdahl, Heike;
Ittrich, Carina;
Graefe-Mody, Ulrike;
Boehm, Bernhard;
Mark, Michael;
Woerle, Hans-Juergen;
Dugi, Klaus

Publication type:

Article

Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus.

Published in:

British Journal of Clinical Pharmacology, 2013, v. 76, n. 3, p. 445, doi. 10.1111/bcp.12077

By:

Friedrich, Christian;
Glund, Stephan;
Lionetti, Dominick;
Kissling, C. James;
Righetti, Julian;
Patel, Sanjay;
Graefe‐Mody, Ulrike;
Retlich, Silke;
Woerle, Hans‐Juergen

Publication type:

Article

Pharmacokinetics of linagliptin in subjects with hepatic impairment.

Published in:

British Journal of Clinical Pharmacology, 2012, v. 74, n. 1, p. 75, doi. 10.1111/j.1365-2125.2012.04173.x

By:

Graefe-Mody, Ulrike;
Rose, Peter;
Retlich, Silke;
Ring, Arne;
Waldhauser, Lisa;
Cinca, Rodica;
Woerle, Hans-Juergen

Publication type:

Article

Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes.

Published in:

PLoS ONE, 2015, v. 10, n. 10, p. 1, doi. 10.1371/journal.pone.0141085

By:

Perkins, Bruce A.;
Cherney, David Z. I.;
Soleymanlou, Nima;
Lee, Justin A.;
Partridge, Helen;
Tschirhart, Holly;
Zinman, Bernard;
Mazze, Roger;
Fagan, Nora;
Kaspers, Stefan;
Woerle, Hans-Juergen;
Broedl, Uli C.;
Johansen, Odd Erik

Publication type:

Article

Linagliptin and pioglitazone combination therapy versus monotherapy with linagliptin or pioglitazone: A randomised, double-blind, parallel-group, multinational clinical trial.

Published in:

Diabetes & Vascular Disease Research, 2016, v. 13, n. 4, p. 286, doi. 10.1177/1479164116639229

By:

Nauck, Michael Albrecht;
di Domenico, Maximiliano;
Patel, Sanjay;
Kobe, Maureen;
Toorawa, Robert;
Woerle, Hans-Juergen

Publication type:

Article

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME).

Published in:

Cardiovascular Diabetology, 2014, v. 13, n. 1, p. 1, doi. 10.1186/1475-2840-13-102

By:

Zinman, Bernard;
Inzucchi, Silvio E.;
Lachin, John M.;
Wanner, Christoph;
Ferrari, Roberto;
Fitchett, David;
Bluhmki, Erich;
Hantel, Stefan;
Kempthorne-Rawson, Joan;
Newman, Jennifer;
Johansen, Odd Erik;
Woerle, Hans Juergen;
Broedl, Uli C.

Publication type:

Article

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.

Published in:

Cardiovascular Diabetology, 2014, v. 13, n. 1, p. 2, doi. 10.1186/1475-2840-13-28

By:

Cherney, David Z. I.;
Perkins, Bruce A.;
Soleymanlou, Nima;
Har, Ronnie;
Fagan, Nora;
Johansen, Odd Erik;
Woerle, Hans-Juergen;
Eynatten, Maximilian von;
Broedl, Uli C.

Publication type:

Article

Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials.

Published in:

Cardiovascular Diabetology, 2013, v. 12, n. 1, p. 1, doi. 10.1186/1475-2840-12-60

By:

von Eynatten, Maximilian;
Gong, Yan;
Emser, Angela;
Woerle, Hans-Juergen

Publication type:

Article

Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia.

Published in:

2016

By:

Ross, Stuart A.;
Caballero, A. Enrique;
Del Prato, Stefano;
Gallwitz, Baptist;
Lewis-D'Agostino, Diane;
Bailes, Zelie;
Thiemann, Sandra;
Patel, Sanjay;
Woerle, Hans-Juergen;
von Eynatten, Maximilian

Publication type:

journal article

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials.

Published in:

2015

By:

Thrasher, James;
Kountz, David S.;
Crowe, Susanne;
Woerle, Hans-Juergen;
von Eynatten, Maximilian

Publication type:

Journal Article

Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes.

Published in:

Kidney International, 2014, v. 86, n. 5, p. 1057, doi. 10.1038/ki.2014.246

By:

Cherney, David Z I;
Perkins, Bruce A;
Soleymanlou, Nima;
Xiao, Fengxia;
Zimpelmann, Joseph;
Woerle, Hans-Juergen;
E Johansen, Odd;
Broedl, Uli C;
von Eynatten, Maximilian;
Burns, Kevin D

Publication type:

Article